Processa holder reports 8.1% stake on Schedule 13G
Rhea-AI Filing Summary
Processa Pharmaceuticals received an amended Schedule 13G showing that investors Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively reported beneficial ownership of 200,000 shares of common stock issuable upon exercise of a warrant held by Intracoastal.
As of December 31, 2025, these warrant shares represented approximately 8.1% of Processa’s common stock, based on 2,265,768 shares outstanding as of December 12, 2025 plus the 200,000 warrant shares. The filers report shared voting and dispositive power over all 200,000 shares and certify the holding is not for the purpose of changing or influencing control.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Processa Pharmaceuticals (PCSA) is reported in this Schedule 13G/A?
Who are the reporting persons in the Processa (PCSA) Schedule 13G/A filing?
How was the 8.1% ownership in Processa (PCSA) calculated in the filing?
Is the Intracoastal Capital LLC position in Processa (PCSA) a passive investment?
What triggered this amended Schedule 13G for Processa Pharmaceuticals (PCSA)?
AI-generated analysis. How Rhea-AI works. Not financial advice.